Wall Street Zen Downgrades Milestone Pharmaceuticals (NASDAQ:MIST) to Sell

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Saturday.

Other equities analysts also recently issued reports about the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a research note on Monday, December 1st. Wells Fargo & Company started coverage on Milestone Pharmaceuticals in a report on Thursday, September 11th. They set an “overweight” rating and a $4.00 price objective on the stock. Two equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Milestone Pharmaceuticals currently has an average rating of “Hold” and an average target price of $4.50.

Milestone Pharmaceuticals Stock Down 18.3%

MIST stock opened at $2.41 on Friday. The stock has a market capitalization of $205.26 million, a PE ratio of -2.94 and a beta of 0.41. The company has a fifty day moving average of $2.18 and a 200-day moving average of $1.91. The company has a debt-to-equity ratio of 2.74, a quick ratio of 8.24 and a current ratio of 8.24. Milestone Pharmaceuticals has a one year low of $0.63 and a one year high of $3.06.

Milestone Pharmaceuticals (NASDAQ:MIST) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.05. As a group, analysts expect that Milestone Pharmaceuticals will post -0.62 EPS for the current year.

Hedge Funds Weigh In On Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Creative Planning boosted its position in Milestone Pharmaceuticals by 74.6% during the second quarter. Creative Planning now owns 23,410 shares of the company’s stock worth $45,000 after purchasing an additional 10,000 shares in the last quarter. Raymond James Financial Inc. boosted its position in shares of Milestone Pharmaceuticals by 30.1% in the 2nd quarter. Raymond James Financial Inc. now owns 43,235 shares of the company’s stock worth $84,000 after buying an additional 10,000 shares in the last quarter. Sapient Capital LLC acquired a new stake in Milestone Pharmaceuticals in the 3rd quarter valued at about $25,000. Bay Rivers Group purchased a new position in Milestone Pharmaceuticals during the 2nd quarter valued at about $28,000. Finally, Bank of America Corp DE raised its position in Milestone Pharmaceuticals by 200,550.0% during the third quarter. Bank of America Corp DE now owns 16,052 shares of the company’s stock worth $32,000 after acquiring an additional 16,044 shares during the last quarter. 86.18% of the stock is owned by institutional investors and hedge funds.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.